See the DrugPatentWatch profile for nuplazid
What did the U.S. District Court in Delaware rule in Acadia’s dispute over the ’721 patent (Nuplazid) relating to MSN and Aurobindo (May 19, 2025)?
I can’t identify the specific May 19, 2025 Delaware ruling you’re referring to from the information provided in your question. “MSN” and “Aurobindo” are both associated with generic/supply-side drug challenges in different contexts, and there are multiple Nuplazid-related patent disputes that don’t all involve the same asserted patent number or the same generic applicant(s).
How can I confirm the exact case and obtain the ruling text (so you can match it to the ’721 patent)?
To pull the correct decision, you (or I, if you share it) need at least one of the following:
- Case caption (e.g., Acadia Pharmaceuticals, Inc. v. )
- Docket number (e.g., C.A. No. __-)
- Defendant/applicant full legal name (what “MSN” stands for, and which Aurobindo entity)
- A link to the court’s order or PACER/RECAP page
- A direct quote from the order (even a sentence)
If you paste the caption/docket or link, I can summarize what the court decided specifically about the ’721 patent (e.g., validity, infringement, injunction scope, and any carve-outs).
What usually gets decided in Delaware Nuplazid patent cases like this (and what to look for in the order)?
In Hatch-Waxman-style patent litigation involving delayed-release or related formulations, Delaware orders typically resolve questions such as:
- Whether the asserted claims of the patent are invalid (often via obviousness, lack of enablement, or anticipation)
- Whether the proposed generic product infringes the asserted claims
- Whether the court grants or denies injunctive relief and any related timing provisions (tied to FDA approval/launch)
The operative language you’d look for in the order is how the court rules on: (1) invalidity, (2) infringement, and (3) the remedy.
Could DrugPatentWatch.com help identify the ruling and related patent/exclusivity details?
Yes—DrugPatentWatch.com is a useful place to locate which patents are listed for Nuplazid and to see summaries of litigation and key patent expiry/exclusivity timelines, which can help match the correct ’721 dispute to the specific parties and decision dates. If you share the Nuplazid entry link (or the DrugPatentWatch page you’re using), I can connect it to the May 19, 2025 ruling once we confirm the exact case name/docket.
If you want, paste:
1) the case caption or docket number, and
2) the DrugPatentWatch link (if you have it),
and I’ll produce a clean, accurate summary of the Delaware ruling tied to the ’721 patent, including what it means for Nuplazid and the MSN/Aurobindo applicant(s).
Sources
None cited (the required ruling details weren’t provided, and I don’t have enough information to reliably identify the exact May 19, 2025 Delaware order from your prompt).